Skip to main content

Lilly Support Services™ agents are ready to support you and your patients.

We’re Here to Help

Lilly Support Services™ for Amyvid®, a free support program, is ready to assist you and your patients through:

Insurance and Coverage Assistance

Lilly Conducted Benefits Investigation: Provides assistance to research patient’s insurance coverage to help identify the lowest out-of-pocket cost, and collects prior authorization or appeals requirements from patient’s insurance provider. A copy of the Summary of Benefits will be sent to the HCP office.

Support is available to answer questions related to Amyvid® (florbetapir F 18 Injection) reimbursement or billing to assist patients with access.

Field Reimbursement Manager (FRM) Support

FRMs are experienced access professionals committed to helping navigate the complex access and reimbursement environment to help patients get access to Amyvid. FRMs are integrated with Support Programs, and understand Support Program resources, access challenges, and affordability options.

Imaging Center Locator

Identify or confirm available Amyvid imaging center options to help your patient locate one that’s convenient for them.

Pre and Post Scan Communications

Communications may be sent to patients before and after their PET scan to keep them informed and feel supported.

To take advantage of flexible enrollment, enroll your patients online or download, complete and fax enrollment form to 1-844-731-2697.

If you have any questions, please call 1-800-LillyRx (1-800-545-5979) Monday-Friday.

DIGITAL ENROLLMENT PORTAL ENROLLMENT FORM

Lilly Support Services™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates

This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.

Download the Amyvid Billing and Coding Guide

Find details about Amyvid billing, including information on the 2023 CMS coverage decision.

DOWNLOAD

Resources that may assist in coverage authorization requests

AMYVID SAMPLE LETTER OF MEDICAL NECESSITY AMYVID SAMPLE OF APPEALS LETTER

PETNET is the exclusive manufacturer and supplier of Amyvid in the United States

PETNET representatives are available to assist with delivery, contracting, and manufacturing questions.

  • Amyvid is available for delivery multiple days per week, and over 109,000* doses have been delivered since FDA approval1
  • Over 96% reliable*† Amyvid dose delivery since FDA approval2

*As of March 2024

†Reliable is defined by a successful dose delivered to an imaging center that can be used.

CMS=Centers for Medicare & Medicaid Services.

References:

  1. Data on File. Lilly USA, LLC. DOF-AM-US-0002.
  2. Data on File. Lilly USA, LLC. DOF-AM-US-0004.

Learn about Amyvid Reader Training

AMYVID READER TRAINING

Important Safety Information

Risk for Image Misinterpretation and Other Errors
  • Errors may occur in the Amyvid estimation of brain neuritic plaque density during image interpretation
  • Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to errors. Other errors may be due to extensive brain atrophy that limits the ability to distinguish gray and white matter on the Amyvid scan as well as motion artifacts that distort the image
  • Amyvid scan results are indicative of the brain neuritic amyloid plaque content only at the time of image acquisition and a negative scan result does not preclude the development of brain amyloid in the future

Radiation Risk

  • Amyvid, similar to other radiopharmaceuticals, contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure

The most common adverse reactions reported in clinical trials were headache (1.8%), musculoskeletal pain (0.7%), blood pressure increased (0.7%), nausea (0.7%), fatigue (0.5%), and injection site reaction (0.5%)

Please see Full Prescribing Information for Amyvid.

AM HCP ISI 14SEP2022

Indication

Amyvid is a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.

Amyvid for intravenous use is supplied in multidose vials containing 500-1900 MBq/mL Florbetapir F 18.

Limitations of Use:

  • A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder
  • Safety and effectiveness of Amyvid have not been established for:
    • Predicting development of dementia or other neurologic condition
    • Monitoring responses to therapies